PEMBROKE,
The transaction, which has now closed, does not include any of the
The Company also reported that in connection with its previously announced strategic review, it is in advanced discussions regarding the sale of its wholly-owned subsidiary,
The completion of the sale of the renewal rights begins the process of simplifying Maiden’s operations, and along with anticipated restructuring and related expense reductions, are expected to improve its business performance and profitability, and significantly reduces the amount of capital required for Maiden’s operations.
“The announcement of this transaction represents an important step in Maiden’s continuing strategic review process and we believe this transaction will increase our financial flexibility, improve our operating efficiency and profitability and broaden our ability to allocate capital to future strategies, which in turn will create value for our shareholders,” said
Metz continued: “We are deeply grateful to the Maiden team for their continued efforts in this challenging environment and, prospectively, we will coordinate closely with clients to ensure a smooth transition.”
About
Forward Looking Statements
This release contains "forward-looking statements" which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company, including forward-looking statements with respect to the potential sale of MRNA, the benefits expected to be derived from the sale of the renewal rights and the achievement of additional operational efficiencies and expense reductions. Readers are cautioned that actual results may differ materially from those projected as a result of significant risks and uncertainties, including the ability to negotiate a satisfactory agreement with respect to the sale of MRNA, delay in achieving improvements (if any) in the Company’s business results and financial positions, non-receipt of expected payments, changes in interest rates, effect of the performance of financial markets on investment income and fair values of investments, developments of claims and the effect on loss reserves, accuracy in projecting loss reserves, the impact of competition and pricing environments, changes in the demand for the Company's products, the effect of general economic conditions and unusual frequency of storm activity, adverse state and federal legislation, regulations and regulatory investigations into industry practices, developments relating to existing agreements, heightened competition, changes in pricing environments, and changes in asset valuations. Additional information about these risks and uncertainties, as well as others that may cause actual results to differ materially from those projected is contained in Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 as updated in periodic filings with the
CONTACT:
Phone: 856.359.2532
E-mail: bhorning@maiden.bm
Source: Maiden Holdings, Ltd.